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Abstract 
Cancer is characterised by somatic genetic variation, but the effect of the majority of              
non-coding somatic variants and the interface with the germline genome are still unknown.             
We analysed the whole genome and RNA-Seq data from 1,188 human cancer patients as              
provided by the ​Pan-cancer Analysis of Whole Genomes (PCAWG) ​project to map ​cis             
expression quantitative trait loci of somatic and germline variation and to uncover the causes              
of allele-specific expression patterns in human cancers. The availability of the first            
large-scale dataset with both whole genome and gene expression data enabled us to             
uncover the effects of the non-coding variation on cancer. In addition to confirming known              
regulatory effects, we identified novel associations between somatic variation and          
expression dysregulation, in particular in distal regulatory elements. Finally, we uncovered           
links between somatic mutational signatures and gene expression changes, including ​TERT           
and ​LMO2​, and we explained the inherited risk factors in APOBEC-related mutational            
processes. This work represents the first large-scale assessment of the effects of both             
germline and somatic genetic variation on gene expression in cancer and creates a valuable              
resource ​ ​cataloguing ​ ​these ​ ​effects. 
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 Introduction 
Cancer is characterised by extensive somatic genetic alterations. These variations can result            
in important cellular phenotypes with relevance for disease, including uncontrolled          
proliferation, immune evasion and metastasis ​(Weir, Zhao, and Meyerson 2004; Knudson           
2002)​. Somatic mutagenesis is in part explained by environmental and intrinsic risk factors,             
with growing evidence for the relevance of the germline background of the patient             
(Pleasance et al. 2010; Jia, Pao, and Zhao 2014; Saini et al. 2016; Nik-Zainal et al. 2014)​.                 
However, the interplay and the functional relevance of these different genetic factors are not              
sufficiently​ ​known.  
One strategy to shed light on this question is association analysis with molecular readouts              
such as gene expression levels. Previous efforts using exome- and transcriptome           
sequencing data from The Cancer Genome Atlas (TCGA, ​Cancer Genome Atlas Research            
Network, Weinstein, et al. 2013 ​) and the International Consortium of Cancer Genomes            
(ICGC, ​J. Zhang et al. 2011 ​) have identified associations between somatic variants in coding              
regions and gene expression. Although these studies have helped to identify and            
characterise regulatory drivers, the role of the much larger number of non-coding somatic             
variants is not fully understood ​(Cancer Genome Atlas Research Network, Kandoth, et al.             
2013; Kanchi et al. 2014)​. Recent studies have begun to address this by identifying genomic               
loci that are recurrently altered by somatic mutations, including their linkages to gene             
expression levels ​(Weinhold et al. 2014; Fredriksson et al. 2014; Smith et al. 2015; Ding et                
al. 2015)​. Additionally, substantial work has focused on the effects of variation in promoters              
of established cancer-genes, including ​TERT and ​BCL2 ​(​Weinhold et al. 2014; Fredriksson            
et al. 2014; Smith et al. 2015; Ding et al. 2015)​. However, thus far, a comprehensive                
analysis of associations between non-coding somatic variation and gene expression is           
missing.  
We carried out joint genetic analyses that integrate coding and non-coding somatic variation             
with germline variants to investigate regulatory effects on gene expression levels in 27             
cancer types. Building on 1,188 consistently processed genomes (whole genome          
sequencing, WGS) and transcriptomes (RNA-Seq) from the Pan-cancer Analyses of Whole           
Genomes (Campbell et al. 2017; PCAWG Consortium 2017) project, we have derived a             
detailed regulatory map that integrates different dimensions of germline and somatic           
variation, including single nucleotide variants (SNVs), somatic copy-number alterations         
(SCNAs) and signatures that capture differences in the prevalence of mutational processes            
across patients. Our approach combines complementary strategies, including allele-specific         
expression (ASE) analyses, somatic and germline expression quantitative trait loci (eQTL)           
mapping and the analysis of gene expression associations with global somatic signatures            
(​Fig.​ ​1 ​).  
Collectively, our analyses provide a comprehensive picture of the regulatory landscape in            
human cancers, thereby identifying previously underappreciated associations between        
somatic regulation in distal regulatory elements and gene expression, as well as ​de novo              
functional annotations of mutational signatures. We report several associations that involve           
cancer-testis (CT) genes with known immunogenic properties ​(R.-F. Wang and Wang 2017;            
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 Scanlan et al. 2002)​, which exhibit high expression in sperm and some cancers but are               
repressed in healthy tissues ​(Simpson et al. 2005)​. Our results point at non-coding somatic              
dysregulation as a functional driver of carcinogenesis beyond mutations of the coding            
sequence ​ ​and ​ ​major​ ​contributor​ ​to ​ ​inter-​ ​and ​ ​intra-tumor​ ​heterogeneity. 
 
Results 
We investigated 1,188 cases of 27 different tumor types obtained as part of the PCAWG               
working group ​(Campbell et al. 2017; Yung et al. 2017; PCAWG Consortium 2017)​, with              
WGS and RNA-Seq data (​Yung et al. 2017; Whalley et al. 2017; Fonseca et al. 2017;                
PCAWG Group 1 2017; PCAWG Group 8 2017; PCAWG Group 3 2017 ​, ​Methods ​). Across              
this panel, we quantified gene expression levels for 18,898 protein-coding genes (FPKM ≥             
0.1, ​in at least 1% of the patients, ​Methods ​), and allele-specific expression (​Methods ​, ​Fig.              
1 ​).  
Germline ​ ​Regulatory​ ​Variants​ ​in ​ ​Cancer 
We considered common germline variants (MAF≥1%) proximal to individual genes ( 100kb          ±  
around the gene) to map eQTL across the entire cohort (​Fig. S2 A​). This pan-cancer               
analysis identified 3,509 genes with an eQTL (FDR ≤ 5%, hereafter denoted eGenes;             
Methods, Table S2 ​), enriched in transcription start site (TSS) proximal regions as expected             
from eQTL studies in normal tissues ​(Bryois et al. 2014 ​, Fig. S2 B​). Analogous              
tissue-specific eQTL analyses in seven cancer types that were represented with at least             
patients identified between 106 (Breast-AdenoCA) and 472 eGenes (Kidney-RCC) (​Fig. S3           
A,​ ​Table ​ ​S2,​ ​Methods ​).  
To identify regulatory variants that are cancer-specific, we compared our eQTL set to eQTL              
maps from normal tissues obtained from the GTEx project ​(GTEx Consortium et al. 2017)​,              
adapting the strategy devised in ​Kilpinen et al. (2017 ​). For each eQTL lead variant, we               
assessed the marginal replication in GTEx tissues (P<0.01, Bonferroni adjusted for 42            
somatic tissues excluding cell lines, using proxy variants r​2​>0.8 for missing variants,            
Methods ​). For 87.5% of the eQTL that could be assessed in at least one GTEx tissue (2,982                 
of altogether 3,408 eQTL, ​Fig. 2D​), this identified a replicating eQTL in at least one GTEx                
tissue, whereas 426 eQTL did not replicate in GTEx tissues, indicating cancer-specific            
regulation of gene expression (​Table S3 ​). One such example is ​SLAMF9​, a member of the               
CD2 subfamily, with known roles in immune response and cancer (​X. A. Zhang et al. 2003 ​,                
Fig. S4 A​). Similarly, we identified cancer-specific eQTL for genes with known roles in              
cancer such as ​SLX1A​, an important regulator of genome stability that is involved in DNA               
repair and recombination and is associated with Fanconi Anemia (​Saito et al. 2012; Medves              
et al. 2016, ​Fig. S4 B​)​. The majority of these cancer-specific regulatory variants could not be                
explained by differences in gene expression level between cancer and normal tissues            
(328/426 exhibit at most a 2-fold increase in median gene expression compared to GTEx,              
e.g. ​SLX1A​, ​Fig. S3 B​), with a remaining set of 98 genes showing clear evidence of                
upregulation or ectopic expression (e.g. ​SLAMF9​). This latter group contained          
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 immunoglobulin genes and nine CT genes including ​RAD21L (​Fig. 2, Fig. S3 B​). We also               
identified instances of eQTL that replicated in GTEx tissues but not in their corresponding              
normal tissues. One such example is ​TEKT5 ​, which is expressed in our cohort but otherwise               
specific to testis in GTEx normal tissues, pointing to upregulation of selected genes in              
cancer​ ​(​Fig.​ ​S3 ​ ​C-E​).  
Allele-specific​ ​Expression ​ ​Captures​ ​Cancer-specific 
Dysregulation 
To robustly identify genetic elements that contribute to somatic dysregulation of gene            
expression, we considered ASE, a locally controlled readout that enables assessing           
differential regulation between haplotypes in the same patient ​(Korir and Seoighe 2014)​. We             
quantified ASE at heterozygous germline variants, following ​Castel et al. (2015) (​Methods)​.            
To maximise detection power, we aggregated ASE counts across heterozygous sites within            
genes, leveraging phased germline variant maps derived using a combination of statistical,            
copy-number (CN) and read-based variant phasing (​Methods ​). This allowed quantification of           
ASE for between 588 and 7,728 genes per patient (median of 4,112 genes with at least 15                 
ASE​ ​reads​ ​in ​ ​1,120 ​ ​patients,​ ​​Fig.​​ ​​S5 ​,​ ​​Methods ​). 
We tested for allelic expression imbalance (AEI) (FDR ≤ 5%, binomial test, ​Methods ​),             
finding substantial differences in the fraction of genes with AEI between cancer types             
(median percentages between 14.2% in Prost-AdenoCA and 46.8% in Lung-SCC among           
tumors; P=2.2x10 ​-13 Mann-Whitney-Wilcoxon Test, ​Fig. 3A​), and between AEI in cancer and            
the corresponding normal tissue (​Fig. 3B​). Cancers with extensive chromosomal          
rearrangements, including lung, breast and ovarian cancers, were associated with most           
frequent AEI events (​Fig. 3A, Fig. S6 ​), which is consistent with previous reports that have               
implicated ​ ​SCNAs​ ​in ​ ​allelic​ ​dysregulation ​ ​in ​ ​cancers​ ​​(Ha ​ ​et​ ​al.​ ​2012)​.  
Motivated by this, we used logistic regression to model the determinants of AEI (​Methods ​),              
accounting for the presence or absence of germline eQTL, local allele-specific SCNAs and             
the mutational burden of proximal somatic SNVs, weighted by their respective cancer cell             
fraction and stratified into functional categories (upstream, downstream, promoter, 5’UTR,          
intron, synonymous, missense, stop gain, 3’UTR, ​Fig. 1 ​, ​Methods ​). In aggregate, SCNAs            
accounted for 86.14% of the explained AEI variability, followed by germline eQTL (9.03%)             
and somatic SNVs (4.83%) (​Fig. 3C​). While cumulatively, non-coding variants were more            
relevant than coding variants (​Fig. 3C​), somatic protein truncating variants (‘stop-gained’)           
were the most predictive individually (​Fig. 3D​), which confirms the importance of            
nonsense-mediated decay (NMD) in cancer gene regulation ​(Lindeboom, Supek, and Lehner           
2016)​. SNVs within splice regions, 5’ UTR and promoters were also strongly associated with              
AEI presence and we observed a global trend of decreased relevance of variants as a               
function of the distance from the TSS (​Fig. 3D​). We also considered a quantitative model on                
ASE ratios using phased variants as features, confirming downregulation of allelic           
expression ​ ​by​ ​NMD​ ​(​Fig.​ ​S7 ​ ​A-D​).  
Using the trained model for AEI, we set out to characterise sets of genes with strong allelic                 
dysregulation that can be attributed to different different genetic factors. ​We ranked genes             
according to average scores across the cohort, based on (i) the predicted AEI from the               
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 germline component and (ii) the predicted AEI from somatic components (SCNAs and SNVs)             
without germline effects. For comparison, we also considered (iii) the empirical AEI            
frequency in the cohort; and (iv) the burden of loss-of-function (LoF) and gain-of-function             
(GoF) mutations derived from genetic data only (​Fig. 3E​). When assessing these rank lists              
using known cancer genes (COSMIC, ​Forbes et al. 2017 ​), we found cancer genes to be               
enriched among genes with high somatic AEI score (P≤0.005, Gene Set Enrichment            
Analysis, ​Subramanian et al. 2005 ​, ​Fig. S8 C​), however we observed no enrichment among              
genes with recurrent AEI (P=0.99, ​Fig. S6 A​). As expected, genes with AEI due to germline                
eQTL were depleted for cancer genes (negative enrichment, P≤0.001, ​Fig. S8 B​). Finally,             
consistent with the traditional definition of cancer genes based on recurrent mutations            
(Forbes et al. 2017)​, genes with recurrent LoF/GoF mutations were most strikingly enriched             
for the COSMIC census (P≤0.001, ​Fig. S8 D​). The top 10% of genes of the somatic AEI                 
scores were enriched for Gene Ontology (GO) categories with relevance to cancer, including             
chemotaxis, cell motility, locomotion and cell migration, which notably were absent when            
considering LoF/GoF mutations (​Fig. 3F​, ​Ashburner et al. 2000; Gene Ontology Consortium            
2015a)​. These results suggest that somatic AEI could be used to prioritise regulatory             
variants to identify genes with roles in cancers, which extends previous observations in a              
single ​ ​cancer​ ​​(Ongen ​ ​et​ ​al.​ ​2014)​​ ​to ​ ​a ​ ​pan-cancer​ ​setting. 
Due to the strong effect of SCNAs on AEI we specifically investigated genes that were               
primarily dysregulated by SNVs. Of the 4,007 genes in the upper quartile based on the               
prevalence of overall AEI across all tumors, 1,843 genes exhibited SNV-linked AEI. When             
we ranked these genes based on the predicted AEI from SNVs, the top 10 genes were                
FBXO5 ​, ​ASPM​, ​PSCA​, ​CDKN1A​, ​KIF20B​, ​TP53 and ​CLDN4, ​which have previously been            
linked to cancer ​(Z. Wang et al. 2014; W.-Y. Wang et al. 2013; Gu et al. 2000; Abbas and                   
Dutta 2009; Liu, Gong, and Huang 2013; Shang et al. 2012; Olivier, Hollstein, and Hainaut               
2010)​, but also ​EXO1 ​, ​SYNE1 and ​STON1-GTF2A1L ​, genes that have not been            
prominently linked to cancer. ​SYNE1 controls nuclear polarity and spindle orientation, which            
is upstream of NOTCH signaling in squamous lineage development ​(Lasorella, Benezra, and            
Iavarone 2014; Garraway and Lander 2013)​. Notably, based on the CADD analysis ​(Kircher             
et al. 2014)​, three melanoma cases preferentially expressed deleterious missense mutations           
(all CADD scores >25) in ​SYNE1​, likely leading to a relative decrease of gene expression in                
these tumors. Based on the GEPIA web server ​(Tang et al. 2017)​, we also found that low                 
SYNE1 expression was associated with worse overall survival in TCGA melanoma patients            
(Log rank P=0.002, Hazard ratio=0.57, ​Fig. S9 A​), providing further support for its relevance              
in disease. ​EXO1 is known to be involved in mismatch repair and recombination, and              
exhibited significant AEI for a deleterious missense (CADD score 34, SIFT score 0, ​Kircher              
et al. 2014; Kumar, Henikoff, and Ng 2009) and a nonsense mutation in a colorectal               
adenocarcinoma patient. Similarly, TCGA colorectal adenocarcinoma patients with lower         
expression of ​EXO1 showed worse overall survival (Log rank P=0.022, HR=0.57, ​Fig. S9 B​),              
implicating ​EXO1 as a potential tumor suppressor in human colorectal cancer. Consistent            
with this finding, ​EXO1 knockout mice exhibited defects in DNA damage response and             
increased ​ ​tumorigenesis​ ​​(Schaetzlein ​ ​et​ ​al.​ ​2013)​. 
Motivated by the observed cancer-specific germline regulation of CT genes, we investigated            
AEI in these genes. Notably, CT genes were depleted when considering the full somatic              
score (SCNAs and SNVs, 25/476 CT genes in the top 10% of genes, 48 expected,               
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 chi-square test, P=6x10 ​-4​), but enriched in the AEI score based on SNVs (66/476 CT genes               
in the top 10% of genes, 48 expected, chi-square test P=0.006). One potential explanation is               
that CT genes with low or no expression in differentiated tissues have to undergo somatic               
re-activation by SNVs before any subsequent SCNA can have an effect. To elucidate this,              
we used mutation timing data (​Gerstung et al. 2017; PCAWG Group 11 et al. 2018 ​,               
Methods ​), stratifying SNVs into the categories ​early (SNV occurred before SCNA at the             
same locus) and ​late (SNV occurred after SCNA at the same locus). We found strong               
over-representation of ​early SNVs in 329 out of 7525 CT gene-patient pairs (216 expected,              
chi-square test, P=3.96x10 ​-14​), suggesting that somatic re-activation of developmental genes          
through ​ ​SNVs​ ​is​ ​selected ​ ​for​ ​and ​ ​precedes​ ​SCNA​ ​events​ ​at​ ​the ​ ​same ​ ​locus. 
Somatic​ ​eQTL ​ ​Mapping ​ ​Reveals​ ​Widespread ​ ​Associations​ ​with 
Non-coding ​ ​Variants  
We next explored the effect of ​cis somatic variation on gene expression by aggregating              
somatic SNVs using local burdens in intronic and exonic genomic intervals (Gencode            
annotations, ​Harrow et al. 2012 ​) and in consecutive genomic intervals within 1Mb from the              
gene boundaries (2kb regions, 1kb overlap, ​Methods ​), hereafter denoted as flanking           
regions. 
Initially, we used these somatic burdens in conjunction with ​cis germline variants and SCNAs              
to decompose variation in gene expression of individual genes into their underlying            
components (​Methods, Fig. 4A​). Consistent with the ASE analysis, this identified SCNAs as             
the major source of variation (27.3% on average across all genes, ​Fig. 4A​), followed by               
flanking somatic and germline variants. Notably, ​cis ​germline effects, although exhibiting           
smaller effects on average, were the largest variance component for 11,905 genes,            
compared to 3,568 genes which variation was primarily explained by somatic factors.            
Consistent with ASE analysis, we observed that non-coding somatic variants had more            
explanatory​ ​power​ ​than ​ ​variants​ ​in ​ ​coding ​ ​regions.  
Next, we tested for associations between recurrently mutated intervals (burden frequency ≥            
1%) and expression levels of individual genes (18,708 protein coding genes; median 952             
intervals per gene, ​Fig. S10 C​), accounting for local and global differences in mutational              
burden across patients as well as tumor purity, cancer type, local SCNAs and other technical               
covariates (​Methods ​). We assessed alternative strategies to estimate mutational burdens          
and found that weighted burden that accounts for variant clonality maximised detection            
power (​Fig. S11 A-D​). Genome-wide, this identified 649 somatic eQTL (FDR ≤ 5%; ​Table              
S6 ​) ​in 567 genomic regions. Among these, 11 somatic eQTL were explained by the              
mutational burden in exons or introns, including genes with known roles in the pathogenesis              
of specific cancers such as ​CDK12 ​in ovarian cancer ​(Bajrami et al. 2013; Ekumi et al.                
2015)​, ​PI4KA ​in ​hepatocellular carcinoma ​(Ilboudo et al. 2014)​, ​IRF4 in leukemia ​(Havelange             
et al. 2011)​, AICDA in skin melanoma ​(Nonaka et al. 2016)​, C11orf73 in clear cell renal                
cancer ​(Bhalla et al. 2017) ​and BCL2 ​and SGK1 ​in lymphoma ​(Weinhold et al. 2014 ​;               
Hartmann et al. 2016 ​, Fig. S12 A-G​). For the majority of 444 eGenes (70%), we observed                
associations with flanking non-coding regions (272 intergenic and 172 intronic regions).           
Hereby, 43.6% of the 567 unique genomic regions were intergenic and did not overlap any               
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 other annotated gene feature (​Fig. 4B)​. The associated elements were generally mutated in             
two or more cancer types (​Fig. S13, Table S6 ​). Unlike germline eQTL, the associations              
tended to be located in distal regions (≥20kb, 88%) with on average larger effect sizes (|               β
|=3.3) than associations in regions proximal to the TSS (| |=1.4) (​Fig. ​S14 ​), which points to         β       
the ​ ​relevance ​ ​of​ ​somatic​ ​mutations​ ​at​ ​distal ​ ​regulatory​ ​elements.  
Motivated by this, we tested lead flanking regions for enrichments in cell type specific              
regulatory annotations in 127 cell types from the Roadmap Epigenomics Project ​(Roadmap            
Epigenomics Consortium et al. 2015) as well as transcription factor binding sites (TFBS)             
from ENCODE (8 cancer cells and one embryonic stem cell line, ​ENCODE Project             
Consortium 2012)​, comparing the overlap of true associations to distance and burden            
frequency matched random regions (​Methods ​). This identified a significant enrichment (FDR           
≤ 10%) of 13 out of 25 epigenetic annotations (​Fig. ​4C​, ​Table S7 ​), including poised               
promoters, weak and active enhancers and heterochromatin in more than two cell lines (​Fig.              
4C​),​ ​but​ ​no ​ ​significant​ ​enrichment​ ​of​ ​TFBS​ ​(​Tables ​​ ​​S8 ​). 
Poised or bivalent promoters are a hallmark of developmental genes and prepare stem cells              
for somatic differentiation ​(Lesch and Page 2014)​. Re-activation of poised promoters is one             
mechanism of upregulation of developmental genes in cancer, including CT genes ​(Bernhart            
et al. 2016)​. CT genes were marginally more frequent among genes with somatic eQTL than               
expected (45/982, P=0.06, Fisher’s exact test), and we observed an enrichment for eQTL in              
bivalent promoters for the CT genes (P=0.04, Fisher’s exact test). One such gene is ​TEKT5,               
an integral component of sperm, that has been found to be aberrantly expressed in a variety                
of cancers ​(Hanafusa et al. 2012)​. We observed a positive association between ​TEKT5             
expression and somatic mutational burden (prevalently observed in non-Hodgkin lymphoma          
patients) in a bivalent promoter site close to the 5’ end of the gene (​Fig. 4D​). The prevalence                  
of developmental genes among the somatic eGenes was also consistent with a global             
enrichment (FDR ≤ 10%) for GO categories related to cell differentiation and developmental             
processes (​Table S9 ​). Together with the ASE analysis, these results emphasise the            
relevance of non-coding genetic variation for changes in gene expression and the            
importance of re-activation of developmental genes through somatic mutations for cancer           
progression. 
Associations​ ​between ​ ​global ​ ​somatic​ ​mutational ​ ​signatures​ ​and 
gene ​ ​expression 
In addition to associations with ​cis elements proximal to genes, it is plausible that global               
differences in mutational states between patients are associated with cell phenotypes,           
including gene expression levels. Global variations in mutational patterns can be quantified            
using mutational signatures which tag mutational processes specific to their tissue-of-origin           
and environmental exposure ​(Alexandrov et al. 2013)​. However, the relationship between           
mutational ​ ​signatures​ ​and ​ ​gene ​ ​expression ​ ​levels​ ​is​ ​unknown.  
We considered 28 mutational signature readouts ​(Forbes et al. 2017) derived using            
non-negative matrix factorization of context-specific mutation frequencies in the PCAWG          
cohort (PCAWG-7 beta 2 release, ​PCAWG Group 7 et al. 2018 ​). We tested for associations               
6 
.CC-BY-NC-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/225441doi: bioRxiv preprint first posted online Nov. 29, 2017; 
 between patient-specific signature prevalence and expression levels of individual genes,          
accounting for total mutational burden and additional technical as well as biological            
confounders (18,831 genes, FPKM filtering of genes across 1,159 patients, ​Methods ​).           
Across all signatures, this identified 1,176 genes associated with at least one signature (FDR              
≤ 10%, ​Fig. S15, ​Methods ​), a markedly different set of genes compared to genes              
associated with the total mutational burden that ignores the assignment to different            
signatures (​Table S10 F​). Lymphoma Signature 9 was associated with the largest set of              
genes,​ ​followed ​ ​by​ ​the ​ ​smoking-related ​ ​Signature ​ ​4 ​ ​(​Fig.​ ​5A,​ ​Tables ​ ​S10 ​ ​A,E,​ ​Fig.​ ​S16 ​ ​D​).  
While aetiologies for some mutational signatures are well understood, others have not            
previously been characterised. To annotate the signatures, we considered 18 signatures           
with at least 20 associated genes and tested for enrichments using GO and Reactome              
Pathways ​(Fabregat et al. 2016; Milacic et al. 2012) categories. Of these, 11 signatures were               
enriched for at least one category (FDR ≤ 10%, ​Table S10 D​), revealing several associations               
that were consistent with known aetiologies (​Fig. 5A​). For example, Signature 9 is known to               
be active in certain lymphomas and leukemias ​(Forbes et al. 2017)​, and was associated with               
354 genes enriched for lymphocyte/leukocyte-related processes and immune response,         
including ​TCL1A​, LMO2 and ​TERT (P=1.22x10 ​-10​, 6.84x10 ​-10​, and 1.96x10 ​-09​). Smoking          
Signature 4 ​(Forbes et al. 2017) was associated with 119 genes, enriched for biological              
oxidation associated processes (e.g. ​processing of benzo[a]pyrene) and including the gene           
CYP24A1​, which is known to be down-regulated in tobacco-smoke exposed tissue (​Fig. ​5B​,             
Woenckhaus et al. 2006)​. We further identified 70 genes ​associated with the APOBEC             
Signature 2 ​(Forbes et al. 2017)​, which were significantly ​enriched for ​DNA deaminase             
pathways.  
Among those signatures with previously unknown aetiology, our results link Signature 8,            
which is primarily prevalent in medulloblastoma ​(Forbes et al. 2017)​, to a set of 25 genes                
enriched for ABCA-transporter pathways, which are targeted by drugs that are ​in clinical             
trials for medulloblastoma ​(Milacic et al. 2012; Ingram et al. 2013)​. Similarly, Signature 38,              
which is correlated with the canonical UV Signatures 7 (e.g. 7a: r​2​=0.375, P=5x10 ​-40​, ​Fig.              
S16 C​), was linked to melanin processes (​Fig. 5A​). Melanin synthesis is known to subject               
melanocytes to oxidative stress by involving main oxidation reactions and superoxide           
anion/hydrogen peroxide generation ​(Kvam and Tyrrell 1999; Denat et al. 2014)​. Our data             
linked Signature 38 to the oxidative stress promoting gene Tyrosinase (​TYR, ​P=1x10 ​-4​,            
Jimbow et al. 2001)​. As Signature 38 is characterised by an excess of C>A mutations, a                
typical product of reactive oxygen species (ROS) mediated by activity of 8-hydroxy-            
2′-deoxyguanosine (DFG, 2010), it might represent DNA damage indirectly caused by UV            
after direct sun exposure due to oxidative damage ​(Premi and Brash 2016)​, with ​TYR ​as a                
possible ​ ​damage ​ ​mediator.  
The cause-and-effect relationship of correlated somatic variations and gene expression          
changes are not clear ​a priori​. To begin addressing the directionality of these linkages, we               
explored the utility of germline variation as an anchor to gain directed mechanistic insights.              
Building on our eQTL map, we queried ​germline eQTL lead variants of mutational             
signature-associated genes and tested for associations between these variants and the           
corresponding mutational signature. This eQTL-guided approach entails substantially fewer         
tests than genome-wide analyses that consider all germline variants ​(Waszak et al. 2017;             
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 PCAWG Group 8 2017)​. Among 1,176 signature-linked genes, 197 also had a germline             
eQTL, but only eQTL variant ​rs12628403 was associated with the respective signature (FDR             
≤ 10%, multiple testing over 197 association tests, ​Table S10 E​). This germline variant is a                
known germline predisposition factor for Signature 2 prevalence ​(Middlebrooks et al. 2016)​,            
an eQTL for ​APOBEC3A/B and significantly associated with Signature 2 prevalence in our             
cohort (P=5.13x10 ​-7​, ​Fig. 5C​). Colocalisation analysis ​(Wallace 2013) confirmed that the           
variant ​rs12628403 is a plausible genetic determinant of both, expression levels of            
APOBEC3A/B and Signature 2 ​(​Table S10 E, ​Methods ​). Finally, we carried out mediation             
analysis ​(Baron and Kenny 1986; Preacher and Hayes 2004) to formally test whether             
expression levels of ​APOBEC3A/B confer the genetic effect to the signature (​Methods ​). We             
found that ​APOBEC3B, POTEI (both P<10 ​-10​) and ​APOBEC3A ​(P​=​0.004) expression levels           
conferred the effect of ​rs12628403 to Signature 2. The proportion of the effect of the variant                
on the signature that is mediated by only ​APOBEC3B expression is a remarkable 87.11%              
(nonparametric​ ​bootstrapping,​ ​1,000 ​ ​simulations,​ ​​Fig.​ ​S17 ​,​ ​​Methods ​). 
 
Discussion 
The regulatory landscape of cancer is highly heterogeneous, cancer type specific and            
influenced by the germline background. This study provides a comprehensive picture of how             
different germline and somatic variations alter gene expression levels. Our results show that             
coregulation of the same genes by multiple different types of variants is common in cancer               
(​Fig. S1 ​). Here, we have assessed the relative magnitudes of these effects (​Fig. 4A​).              
Previous studies have been limited by the lack of whole genome sequencing data, which is               
essential for identifying contributions of non-coding variants to gene expression variability.           
Indeed, our analysis which is based on data from the currently largest cohort of matched               
tumor WGS and RNA-Seq data of 1,188 patients, demonstrates that the impact of             
non-coding ​ ​variation ​ ​can ​ ​be ​ ​profound. 
We have produced comprehensive across-tissue and tissue-specific germline eQTL maps          
and have identified associated genetic risk variants. By comparing these cancer eQTL maps             
to the GTEx catalogue, we have observed substantial overlap between cancer and normal             
tissues, but also a smaller number (12.14%) of potentially interesting cancer-specific eQTL.            
This estimate is conservative since we have assessed replication in any GTEx tissues and              
not only in the corresponding normal tissues. In selected cases we have observed that eQTL               
in cancer mimic regulatory effects in other non-corresponding tissues, in particular           
testis-specific​ ​genes​ ​(​Fig.​ ​2A​).  
In parallel to germline eQTL, we have considered the effect of somatic mutational burden in               
different genomic regions on gene expression changes by building a systematic map of             
somatic eQTL. Our analysis accounts for variation in clonality as well as local             
hypermutations, thereby identifying likely causal associations between somatic burden and          
gene expression. However, this approach has limitations and we cannot rule out that a              
fraction of the associations we have identified are due to technical or biological factors that               
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 jointly affect gene expression and local mutation rates. We also note that an analysis of               
cancer​ ​type ​ ​specific​ ​somatic​ ​eQTL ​ ​is​ ​currently​ ​not​ ​feasible ​ ​with ​ ​the ​ ​given ​ ​sample ​ ​size. 
We have used ASE readouts for integrated modelling of genetic variation in ​cis and              
fine-grained characterisation of the genetic elements that have the largest regulatory effects.            
We have demonstrated the extent to which AEI follows allelic imbalance on the genomic              
level. While ASE is sensitive to heterozygous genetic variation, the considered phased            
somatic mutation set is based on read phasing, which has only been possible for around               
20% of all SNVs. Further, ASE readouts can only be derived in cases with at least one                 
heterozygous germline variant in the gene in question, reducing overall sample size and             
hindering ​ ​gene-level ​ ​associations.  
Our analysis suggests somatic re-activation of CT genes through SNVs, supported by            
mutation timing analysis. ​CT genes were also enriched in cancer-specific germline and            
somatic eGenes linked to SNV burden in nearby bivalent promoters. ​Somatic eQTL were             
further enriched for tissue development and differentiation. Due to the low number of             
expressed CT genes these findings need to be evaluated on additional data. However, we              
have found CT gene implicated in three out of four independent analyses (germline eQTL,              
somatic​ ​eQTL ​ ​and ​ ​ASE),​ ​reinforcing ​ ​the ​ ​potential ​ ​impact​ ​of​ ​these ​ ​findings. 
Mutational signatures capture global variations across individuals, for example due to           
environmental factors or exogenous damage, which are distinct from local somatic variations            
assessed using QTL mapping and ASE. We have explored the utility of associations             
between these mutational signatures and gene expression levels, thereby deriving ​de novo            
annotations of signatures with previously unknown roles. Finally, we have carried out proof             
of concept analyses to integrate germline factors, somatic variants and gene expression,            
thereby unpicking the molecular chain of events for the common APOBEC mutational            
process and its germline component. Due to the tissue specificity of mutational signatures, it              
will be important to conduct similar analyses for individual cancer types and in cohorts with               
larger​ ​sample ​ ​sizes.  
This is the first large-scale study assessing the effects of both germline and somatic genetic               
variation on gene expression from WGS data in a pan-cancer setting. The somatic and              
germline eQTL resources will be a valuable resource to address a wide range of              
downstream analyses, ​providing a comprehensive overview of gene expression         
determinants in cancer and insights into the underlying biology. The systematic assessment            
of regulatory non-coding genetic variation significantly improves our understanding of the           
aetiology and functional implications of intra- and inter-tumor heterogeneity and the selective            
forces​ ​applied ​ ​to ​ ​these ​ ​heterogeneous​ ​genomes. 
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 Figures 
 
 
 
 
Fig. 1. ​Integrative analysis approach for assessing the regulatory landscape in human            
cancers and overview of different classes of genetic variation considered here. ​A) ​Cis             
genetic effects of individual germline variants (blue) on gene expression were assessed            
using eQTL mapping. Somatic variants (red) were aggregated in mutational burden           
categories and assessed using i) ASE, ii) gene level ​cis eQTL and iii) associations with               
mutational signatures in patients. ​B) Data sources and processing steps, including germline            
and somatic variant calling from WGS data and allele-specific expression quantification from            
RNA-seq. 
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Fig. 2. ​Germline eQTL analysis. ​A) Manhattan plot for ​RAD21L1​, showing associations in             
the ICGC cohort (blue) and in GTEx testis tissue (green). ​B) Boxplots of the effect of the                 
eQTL lead variant for ​RAD21L in the ICGC cohort. Colors denote cancer types of individual               
patients. ​C) ​Gene expression distribution of ​RAD21L ​across GTEx tissues and ICGC cancer             
types. ​RAD21L expression is increased in testis tissue, breast adenocarcinoma patients           
(‘Breast-AdenoCA’) and leukemia cell lines. ​D) ​The Venn diagram shows the number of             
eQTL identified in the ICGC cohort and the fraction of QTL that replicate in the GTEx cohort.                 
426 ​ ​eQTL ​ ​were ​ ​specific​ ​to ​ ​the ​ ​ICGC​ ​cohort. 
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Fig. 3. ​Allele-specific expression analysis. A) ​Distribution of the proportion of genes with             
significant allele-specific imbalance (AEI, FDR ≤ 5%) (red) and SCNAs (blue) across patients             
for different cancer types. Cancer types with prevalent chromosomal instability (frequent           
SCNAs) exhibit most frequent AEI. ​B) Proportion of genes with AEI (FDR ≤ 5%) in tumor and                 
matched normal RNAseq patients across the cohort. ​C) Effect sizes of SCNAs, germline             
eQTL, coding and non-coding variants on AEI status. ​D) ​Relevance of individual somatic             
mutation types, germline eQTL and other co-variates for AEI status. Significant covariates            
(FDR ≤ 5%) highlighted in bold. ​E) COSMIC cancer gene enrichment for the four models of                
gene dysregulation: (i) average observed AEI frequencies (green); (ii) predicted germline           
AEI (purple); (iii) predicted somatic AEI excluding germline (blue), and (iv) LoF and GoF              
mutations (red). ​F) Enrichment of top 10% of genes ranked according to LoF/GoF mutations              
(red)​ ​or​ ​predicted ​ ​somatic​ ​AEI​ ​(blue),​ ​using ​ ​GO​ ​ontologies​ ​(FDR​ ​≤​ ​5%). 
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Fig. 4. ​Somatic burden eQTL analysis. ​A) Variance component analysis for gene expression             
levels (​Methods ​). Shown is the average proportion of variance explained by different            
germline and somatic factors for different sets of genes, considering genes for which the              
largest variance component are i) copy number effects (CNV), ii) somatic variants in flanking              
regions, iii) ​cis germline effects and iv) somatic intron and exon mutations, respectively. The              
number of genes in each set is indicated in ​parentheses​. ​B) Breakdown of 567 genomic               
regions that underlie the observed ​cis somatic eQTL by variant category (Intronic = eGene              
intron; Exonic = eGene exon; Flank. = 2kb flanking region within 1Mb distance to the eGene                
start; Flank.intergenic = flanking region in a genomic location without gene annotations;            
Flank.intronic = flanking region overlapping an intron of a nearby gene; Flank.others =             
flanking region partially overlapping exonic and intronic annotations of a nearby gene). ​C)             
Maximum fold enrichment of epigenetic marks from the Roadmap Epigenomics Project           
across 127 cell lines. The number of cell lines with significant enrichments is indicated in               
parentheses (FDR ≤ 10%); asterisks denote significant enrichments in at least one cell line.              
D) Manhattan plot showing nominal p-values of association for ​TEKT5 ​(highlighted in gray),             
considering flanking, intronic and exonic intervals. The leading somatic burden is associated            
with increased ​TEKT5 expression (P=1.56x10 ​-06​; =0.221) and overlaps an upstream     β      
bivalent promoter (red box; annotated in 81 Roadmap cell lines, including 8 ESC, 9              
ES-derived and 5 iPSC cell lines). The inset boxplot shows a positive association between              
the ​ ​mutation ​ ​status​ ​and ​ ​expression ​ ​levels.  
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Fig. 5. ​Associations between mutational signatures and gene expression ​. A) Summary of            
significant associations. Top panel: Total number of associated genes per signature (FDR ≤             
10%). Bottom panel: Enriched GO categories or Reactome pathways for genes associated            
with each signature (FDR ≤ 10%, significance level encoded in color, -log ​10 P​adj ​). ​B)              
Representative signature-gene association, depicting a negative association between        
CYP26A1 expression and Signature 4. ​C) ​Manhattan plots of associations between ​cis            
germline variants proximal to ​APOBEC3B ​(plus or minus 100kb from the gene boundaries)             
and Signature 2 (top panel) or ​APOBEC3B gene expression level (bottom panel). The gray              
region ​ ​denotes​ ​the ​ ​gene ​ ​body,​ ​the ​ ​orange ​ ​variant​ ​the ​ ​lead ​ ​eQTL ​ ​variant​ ​​rs12628403 ​. 
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